Antares Pharma Announces Completion Of Patient Enrollment In Phase 3 Pivotal Trial Of Anturol™ For The Treatment Of Overactive Bladder
Links shared publicly online about this topic.
- 1,339total visits
Antares Pharma Announces Completion Of Patient Enrollment In Phase 3 Pivotal Trial Of Anturol™ For The Treatment Of Overactive Bladder
View full resource at medicalnewstoday.com
Tags: Urinary System, Overactive Bladder, Overactive Bladder Medication, Pharma, Phase 3 Clinical Trial, Clinical Trial, Bladder Dysfunction
Most Recently Shared on March 4, 2010 at 4:12 pm By:
Antares Pharma Announces Completion Of Patient Enrollment In Phase 3 Pivotal Trial Of Anturol™ For The Treatment... http://mnt.to/3ysd
Antares Pharma completes enrollment in Phase 3 clinical trial of Anturol for OAB
news-medical.net — “Antares Pharma, Inc. announced today that it has completed enrollment in the double-blind portion of the Company's Phase 3 clinical trial of Anturol", its transdermal oxybutynin ATD" gel for the treatment of overactive bladder (OAB). Top line data from this pivotal trial, which is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA), is expected in the third quarter of this year.” View full resource at news-medical.net
Most Recently Shared on March 2, 2010 at 2:08 pm By:
Antares Pharma completes enrollment in Phase 3 clinical trial of Anturol for OAB: Antares Pharma, Inc. announced t... http://bit.ly/c5DxQc
Advertisement
